Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL15564463

Cc1ccc2c(c1)O[C@@H](C)[C@H](N)C(=O)N2.O=C(O)C(F)(F)F

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.39
MAPT P10636 1/20 0.39
XBP1 P17861 1/20 0.39
HTT P42858 1/20 0.39
PAX8 Q06710 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
USP2 O75604 1/20 0.37
GAA P10253 1/20 0.37
HSD17B10 Q99714 2/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 2/20 0.35
MEN1 O00255 3/20 0.35
PTGS2 P35354 1/20 0.35
BRD4 O60885 3/20 0.34
CREBBP Q92793 2/20 0.34
HSD17B1 P14061 1/20 0.33
HSD17B2 P37059 1/20 0.33
PARP1 P09874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15594303 0.89 BRD4 (0.41) KMT2AUSP2GAAHSD17B10ALOX15
Trifluoroacetic Acid SCHEMBL4799215 0.84 PARP1 (0.51) KMT2AMAPTHTTUSP2GAA
Trifluoroacetic Acid SCHEMBL4800639 0.84 PARP1 (0.51) KMT2AMAPTHTTUSP2GAA
Trifluoroacetic Acid SCHEMBL15565599 0.80 ACE2 (0.38) KMT2AMAPTHTTUSP2GAA
SCHEMBL1562063 0.79 BRD4 (0.43) KMT2AMAPTHTTUSP2HSD17B10
Trifluoroacetic Acid SCHEMBL15565133 0.79 KMT2A (0.39) KMT2AMAPTXBP1HTTPAX8
SCHEMBL8904957 0.77 PARP1 (0.40) KMT2ABRD4CREBBPPARP1
SCHEMBL8904960 0.77 PARP1 (0.40) KMT2ABRD4CREBBPPARP1
SCHEMBL15565283 0.75 USP2 (0.43) KMT2AHTTUSP2GAAHSD17B10
SCHEMBL5672049 0.72 PARP1 (0.62) KMT2AUSP2GAATSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394263-B2 Substituted hetero-azepinones F. HOFFMANN-LA ROCHE AG (CH) 2016-07-19 US disclosed
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES HOFFMAN-LA ROCHE INC. (US) 2015-12-17 US disclosed
EP-2882725-A1 SUBSTITUTED HETERO-AZEPINONES F. Hoffmann-La Roche AG (CH) 2015-06-17 EP disclosed
WO-2014023708-A1 SUBSTITUTED HETERO-AZEPINONES F. HOFFMANN-LA ROCHE AG (CH) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150361059-A1 SUBSTITUTED HETERO-AZEPINONES CCNY, CCNE1, CCND3 KMT2A 1137/4885MAPT 4794/4885XBP1 2069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.